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Abstract
Background: Anaemia is common in patients with chronic kidney disease (CKD) and can be
managed by therapy with erythropoiesis-stimulating agents (ESAs). Epoetin delta (DYNEPO®, Shire
plc) is the only epoetin produced in a human cell line. The aim of this study was to demonstrate
the safety and efficacy of subcutaneously administered epoetin delta for the management of
anaemia in CKD patients (predialysis, peritoneal dialysis or haemodialysis)
Methods: This was a 1-year, multicentre, open-label study. Patients had previously received
epoetin subcutaneously and were switched to epoetin delta at an identical dose to their previous
therapy. Dose was titrated to maintain haemoglobin at 10.0–12.0 g/dL. The primary endpoint was
mean haemoglobin over Weeks 12–24. Secondary analyses included long-term haemoglobin,
haematocrit and dosing levels. Safety was assessed by monitoring adverse events, laboratory
parameters and physical examinations.
Results: In total 478 patients received epoetin delta, forming the safety-evaluable population.
Efficacy analyses were performed on data from 411 of these patients. Mean ± SD haemoglobin over
Weeks 12–24 was 11.3 ± 1.1 g/dL. Mean ± SD weekly dose over Weeks 12–24 was 84.4 ± 72.7
IU/kg. Haemoglobin levels were maintained for the duration of the study. Epoetin delta was well
tolerated, with adverse events occurring at rates expected for a CKD patient population; no
patient developed anti-erythropoietin antibodies.
Conclusion: Subcutaneously administered epoetin delta is an effective and well-tolerated agent
for the management of anaemia in CKD patients, irrespective of dialysis status.
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Background
Chronic kidney disease (CKD) is a prevalent and increas-
ing health concern worldwide, and anaemia is a frequent
complication of CKD [1,2]. The main cause of anaemia in
patients with CKD is insufficient synthesis of erythropoi-
etin by the damaged kidney. Since the 1980s, erythropoi-
esis-stimulating agents (ESAs) have been used to treat
CKD-associated anaemia. Anaemia management with
ESAs is a successful and well-tolerated therapy that has
been demonstrated to improve quality of life and posi-
tively influence outcomes [3-6].
Until now ESAs have all been recombinant erythropoie-
tins produced in Chinese hamster ovary (CHO) cell lines,
however a new epoetin, epoetin delta (DYNEPO®, Shire
plc), is the only one produced in a human cell line [7,8].
Epoetin delta has an identical amino acid structure to
endogenous human erythropoietin, as is also the case for
epoetin alfa and epoetin beta [7]. However differences in
glycosylation profile between epoetin delta and the CHO-
cell-derived epoetins have been demonstrated, such as
lower levels of certain non-human carbohydrate residues
(N-glycolylneuraminic acid) in epoetin delta [8].
Phase II clinical trials with epoetin delta demonstrated
that it is effective in increasing haemoglobin levels when
administered intravenously (three times per week) to
haemodialysis patients [9] and subcutaneously (twice per
week) to CKD patients not on dialysis [10]. A 24-week,
phase III trial in haemodialysis patients comparing epoe-
tin delta and epoetin alfa, administered intravenously
three times per week, demonstrated equivalent efficacy
between the two agents [11]. An open-label extension to
the study showed continued efficacy of epoetin delta in
this haemodialysis population throughout the 52 weeks
of study [12]. Efficacy of epoetin delta in a subgroup of
predialysis patients has also been previously described
[13]. Epoetin delta was well tolerated in all of these phase
II and phase III studies. Additionally, phase I and II stud-
ies demonstrated that the half-life of subcutaneously
administered epoetin delta is similar to the half-life of
epoetin beta [14], an agent that can be administered once
per week, and even once every 2 weeks in maintenance
patients [15,16].
Here, we report on an open-label, phase III study to assess
the efficacy and safety of epoetin delta, administered sub-
cutaneously once, twice or three times per week for the
treatment of anaemia in haemodialysis, peritoneal dialy-
sis and predialysis patients with CKD.
Methods
Patients
Patients with CKD (aged 18 years or older) and a medical
history of anaemia (defined as haemoglobin < 11 g/dL)
were eligible to enter the study. Predialysis patients had
serum creatinine > 2 mg/dL (176.8 μmol L-1) or creatinine
clearance rates of < 45 mL/min (by either 24-h urine col-
lection or Cockcroft-Gault formula), equating to CKD
stage 3 or 4. All patients had haemoglobin levels in the
range of 9.6–12.4 g/dL for the 2 weeks before entering the
study. In the 30 days before entering the study haemodi-
alysis patients were receiving an epoetin (epoetin alfa or
beta) subcutaneously, two or three times per week, while
peritoneal dialysis patients and those not on dialysis were
receiving an epoetin subcutaneously at least once per
week. During this 30-day period the dose of the epoetin
had not changed by > 50% (either increase or decrease).
Patients had to have serum ferritin ≥ 90 ng/mL and trans-
ferrin saturation ≥ 18% at the prestudy measurement. Suf-
ficient iron to maintain serum ferritin ≥ 100 ng/mL and
transferrin saturation ≥ 20% was specifically required dur-
ing the study. If iron status measurements fell short of
these criteria then patients received intravenous iron sup-
plementation of at least 1000 mg, over a maximum of 10
weeks. For haemodialysis patients, iron was administered
within the first 90 minutes of the dialysis session. At study
centres in France oral iron supplementation was
attempted before use of the intravenous route for predial-
ysis and peritoneal dialysis patients, and for haemodialy-
sis patients intravenous iron therapy was initiated within
the first few minutes of the dialysis session.
Exclusion criteria included uncontrolled hypertension,
concomitant illness that could reduce life expectancy to <
12 months, thrombocytopenia (platelet count < 75 000/
mm3), impaired hepatic function, previous treatment
with epoetin delta, and pregnancy or breastfeeding at the
prestudy screening. Also excluded were women of child-
bearing potential not using effective contraceptive meth-
ods.
The study was performed in accordance with the Declara-
tion of Helsinki and was approved by local ethics commit-
tees at the individual study centres. All patients gave
written informed consent before undergoing any study
related procedures.
Study Design
This was a multicentre, open-label, uncontrolled study to
assess the safety and efficacy of subcutaneously adminis-
tered epoetin delta over 1 year. The study was carried out
at sites in the USA and Europe between 1998 and 2000.
Epoetin delta was administered subcutaneously once,
twice or three-times per week, at the same frequency as
patients received before entering the study. The initial
dose of epoetin delta was identical to the last dose of epo-
etin the patient received before entering the study. ThisBMC Nephrology 2009, 10:5 http://www.biomedcentral.com/1471-2369/10/5
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dose was maintained for 2 weeks with subsequent titra-
tion to maintain haemoglobin at 10–12 g/dL, in keeping
with the European Best Practice Guidelines in place at the
time of the study [17]. Titration was as follows: dose was
increased by 50% if haemoglobin dropped below 10 g/dL
or decreased by 25% if haemoglobin was above 12 g/dL.
Dose was also altered if a patient's dry weight changed by
more than 5 kg. Dose adjustment based on haemoglobin
level was only performed once in every 4-week period.
Endpoints and analysis
Haematological parameters were assessed weekly for the
the first 12 weeks of the study and thereafter every 4
weeks. The primary efficacy endpoint was average haemo-
globin over Weeks 12, 16, 20 and 24. Efficacy analyses
were performed on data from a modified intent-to-treat
(mITT) population consisting of all patients who had a
valid haemoglobin measurement at baseline and at least
one haemoglobin measurement during Weeks 12, 16, 20
or 24. An analysis of the primary endpoint was also car-
ried out in the ITT population using last observation car-
ried forward and first observation carried back techniques.
In addition, an adjusted average haemoglobin was calcu-
lated with an ANCOVA model including parameters for
dialysis type, pooled centre, and covariates of baseline
haemoglobin and baseline epoetin dose.
Secondary analyses included: epoetin delta dose levels;
descriptive statistics of haemoglobin and haematocrit lev-
els; the proportion of patients' haemoglobin values over
10 g/dL and the proportion of patients' haematocrit val-
ues over 30% during Weeks 12–24; and haematological
parameters and dosing over the 52 weeks of the study.
Safety assessments were conducted by recording and
monitoring adverse events at each visit. Laboratory safety
assessments were carried out every 4 weeks, and physical
examinations and ECG at baseline, mid-study and at the
end of the study (or early withdrawal). Anti-erythropoie-
tin antibodies were screened for by validated ELISA
(Quintiles Inc., Kansas City, MO) on samples collected at
baseline and then every 4 weeks for the duration of the
trial.
Results
Patients
Of 865 patients screened, 478 met the inclusion criteria
and entered the study (Figure 1), forming the ITT popula-
tion. All patients in the ITT population received at least
one dose of epoetin delta and were included in the safety-
evaluable population. The mITT population consisted of
411 (86.0%) patients. This decrease from the ITT popula-
tion is not surprising, given that criteria for inclusion in
this group required completion of 12 weeks of treatment.
The majority of haemodialysis patients received epoetin
delta three-times or twice per week, while the majority of
peritoneal dialysis and predialysis patients received epoe-
tin delta once per week (Table 1). Baseline demographics
for the mITT population are shown by both dialysis type
and frequency of epoetin delta administration (Table 2).
The most common primary diagnoses for the causes of
CKD were hypertensive nephrosclerosis (118/411;
28.7%) and diabetic nephropathy (97/411; 23.6%).
Overall 34.5% (142/411) of patients had a medical his-
tory of either Type 1 or Type 2 diabetes.
Overall mean ± SD haemoglobin at baseline was 11.1 ±
0.9 g/dL (mean haematocrit of 35.0 ± 3.0%) and haemo-
globin levels were similar across all dialysis types and
administration frequencies (Table 3).
Of those patients receiving study medication, 366/478
(76.6%) completed 24 weeks of treatment and 319/478
(66.7%) completed the study. The most common reasons
for withdrawal in the first 24 weeks were: red blood cell
transfusion (27/112; 24%); patient did not wish to con-
tinue (13/112; 11.6%) and death (13/112; 11.6%). In
addition 19 patients in Europe were withdrawn because of
a sterility test failure on a batch of study drug. Subsequent
Patient flow through the study Figure 1
Patient flow through the study.BMC Nephrology 2009, 10:5 http://www.biomedcentral.com/1471-2369/10/5
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investigation indicated that no contamination of drug
substance was present and there was a high probability
that external contamination of the cap was responsible for
the test failure. Other reasons for discontinuation
included: missed more than six doses (n = 8); kidney
transplant (n = 8); patient no longer met entry criteria (n
= 7); adverse event (n = 6); patient transferred to another
facility (n = 3); patient not previously prescribed an epoe-
tin according to protocol for dialysis type (n = 3); miscel-
laneous (chemotherapy, surgery, investigator decision [n
= 3]) and screening results not received in time (n = 2).
The most common reasons for withdrawal during Weeks
24–52 were death (15/366; 4.1%), worsening adverse
event (9/366; 2.5%), patient did not wish to continue (8/
366; 2.2%), red blood cell transfusion (4/366; 1.1%) and
kidney transplant (4/366; 1.1%).
Efficacy assessments
Overall mean ± SD haemoglobin level for Weeks 12–24
was 11.3 ± 1.1 g/dL, with mean haemoglobin levels main-
tained at 10–12 g/dL (within the target range) irrespective
of dialysis type or administration frequency in the mITT
Table 1: Frequency of administration by dialysis type and total patients (mITT population; N = 411)
Number (%) of patients
Frequency of administration Predialysis (n = 32) Haemodialysis (n = 288) Peritoneal dialysis (n = 91) Total (N = 411)
3× per week 0 152 (52.8) 6 (6.6) 158 (38.4)
2× per week 2 (6.3) 131 (45.5) 17 (18.7) 150 (36.5)
1× per week 30 (93.8) 5 (1.7) 68 (74.7) 103 (25.1)
Table 2: Baseline demographics by frequency of administration, dialysis type and total patients (mITT population; N = 411)
Number (%) of patients (except as noted)
By frequency of administration By dialysis type
3× weekly 
(n = 158)
2× weekly 
(n = 150)
1× weekly 
(n = 103)
Predialysis 
(n = 32)
Haemo-dialysis 
(n = 288)
Peritoneal 
dialysis (n = 91)
Total (N = 411)
Sex
Male 101 (63.9) 82 (54.7) 50 (48.5) 13 (40.6) 175 (60.8) 45 (49.5) 233 (56.7)
Female 57 (36.1) 68 (45.3) 53 (51.5) 19 (59.4) 113 (39.2) 46 (50.5) 178 (43.3)
Age (Years)
Mean
(± SD)
59.4 (15.9) 60.5 (15.5) 56.7 (14.4) 63.9 (12.4) 60.7 (15.6) 52.4 (14.0) 59.2 (15.42)
Median (range) 61
(19–87)
64
(19–85)
58
(26–86)
66
(29–86)
64
(19–87)
53
(24–86)
61
(19–87)
Race
Caucasian 110 (69.6) 111 (74.0) 64 (62.1) 26 (81.3) 212 (73.6) 47 (51.6) 285 (69.3)
Black 41 (25.9) 34 (22.7) 32 (31.1) 6 (18.8) 67 (23.3) 34 (37.4) 107 (26.0)
Asian or 
Oriental
2 (1.3) 0 (0.0) 3 (2.9) 0 (0.0) 1 (0.3) 4 (4.4) 5 (1.2)
Multiracial 5 (3.2) 5 (3.3) 4 (3.9) 0 (0.0) 8 (2.8) 6 (6.6) 14 (3.4)BMC Nephrology 2009, 10:5 http://www.biomedcentral.com/1471-2369/10/5
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population (Table 3). A similar overall value was obtained
in the ITT population (11.3 ± 1.1 g/dL). The adjusted aver-
age level was 11.1 ± 0.1 g/dL, indicating that dialysis type,
baseline haemoglobin level and baseline dose did not
greatly affect the results. Mean ± SD haematocrit was 36.4
± 3.7% over Weeks 12–24, and mean haematocrit during
this period was > 36% for all dialysis subgroups and
administration frequencies (data not shown). Over Weeks
12–24, 83.9% of haemoglobin measurements and 92.3%
of haematocrit measurements were above the predefined
lower limits of 10 g/dL and 30% respectively. Analyses of
haemoglobin for the 52-week duration of the study,
showed levels were maintained at 10–12 g/dL (Figure 2).
The average weekly doses over Weeks 12–24 and Weeks
37–52 are shown in Table 4, both by dialysis type and fre-
quency of administration. Median dose was lowest for
predialysis patients and highest for haemodialysis
patients over Weeks 12–24. There were no marked differ-
ences in dose between Weeks 12–24 and Weeks 37–52.
Mean and median weekly dose generally decreased with
decreasing administration frequency, though the case mix
in the three groups was different.
Safety and tolerability
Overall 86.8% (415/478) of patients experienced an
adverse event during treatment, in line with the levels
expected considering the baseline disease characteristics
of this population. The most commonly reported adverse
events were upper respiratory tract infection (19.5%),
infection (18.2%), hypotension (16.7%), headache
(14.4%) and muscle cramps (13.6%). Overall, adverse
events considered possibly related to treatment occurred
in 12.3% (59/478) of patients (Table 5). The most com-
monly reported were hypertension and thrombosis. Seri-
ous adverse events (SAEs) were reported by 236/478
(49.4%) of patients, with rates similar across all dialysis
types. SAEs considered possibly related to study medica-
tion occurred in 4.6% (22/478) of patients, and the
majority of these were reported for patients undergoing
haemodialysis (17/22; 77.3%). Adverse events leading to
withdrawal from the study occurred in 3.1% (15/478) of
Table 3: Haemoglobin levels by frequency of administration, dialysis type and total patients (mITT population; N = 411)
Average haemoglobin (g/dL) (mean ± SD)
Population by: Baseline Weeks 12–24
Frequency of administration
3× per week (n = 158) 11.0 ± 0.9 11.2 ± 1.1
2× per week (n = 150) 11.1 ± 0.8 11.3 ± 1.1
1× per week (n = 103) 11.1 ± 0.9 11.5 ± 1.2
Dialysis type
Predialysis (n = 32) 10.9 ± 0.8 11.3 ± 1.2
Haemodialysis (n = 288) 11.1 ± 0.8 11.2 ± 1.1
Peritoneal dialysis (n = 91) 11.2 ± 0.9 11.6 ± 1.1
Total (N = 411) 11.1 ± 0.9 11.3 ± 1.1
Mean (± SD) haemoglobin during the 52 weeks of study Figure 2
Mean (± SD) haemoglobin during the 52 weeks of 
study.BMC Nephrology 2009, 10:5 http://www.biomedcentral.com/1471-2369/10/5
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patients, with six events considered possibly related to
study medication (angio-oedema, hypertensive encepha-
lopathy, hypertension, nausea, skin ulcers, pruritus).
Mean changes in laboratory analytes, vital signs and body
weight from baseline to endpoint were minimal and there
was no tendency for epoetin delta to induce ECG changes.
During the 52 weeks of this trial no patient developed
anti-erythropoietin antibodies or pure red cell aplasia.
Discussion
Results from this open-label study show that subcutane-
ously administered epoetin delta, the only human-cell-
derived epoetin, was effective for the control of anaemia
in this group of CKD patients (predialysis, peritoneal dial-
ysis and haemodialysis) over 52 weeks. During the pri-
mary period of assessment (Weeks 12–24) haemoglobin
levels were maintained within the target range of 10–12 g/
dL, in line with current recommendations [6]. Over 80%
of haemoglobin and 90% of haematocrit measurements
were above the predefined lower limits of 10 g/dL and
30% respectively. A switch from prestudy therapy with
subcutaneous epoetin alfa to subcutaneous epoetin delta
was associated with continued control of haemoglobin
levels for up to 1 year, across all dialysis types and admin-
istration frequencies of once, twice and three times per
week. Epoetin delta was well tolerated for the duration of
the study and no patient developed anti-erythropoietin
antibodies or pure red cell aplasia.
The data demonstrate that epoetin delta is an acceptable
alternative to other epoetins. It would appear that patients
can be transitioned from other epoetins to epoetin delta
at the same dose with no loss of control of anaemia. As
noted previously, epoetin delta differs from other ESAs in
that it is produced in a human cell line. It is not known
whether this leads to any clinical advantages, but in theory
it is possible that a different glycosylation pattern may
have an impact on the pleiotropic effects of the agent. This
requires further investigation.
Table 4: Average weekly doses by frequency of administration, dialysis type and total patients (mITT population; N = 411)
Average weekly doses (IU/kg)
Population by Weeks 12–24 Weeks 37–52
Frequency of administration n (%) Mean ± SD Median (Range) n (%) Mean ± SD Median (Range)
3× per week 158 (100.0) 103.5 ± 88.0 77.9 (13.3–804.0) 126 (79.8) 114.4 ± 130.7 90.5 (0.0–1293.6)
2× per week 150 (100.0) 76.9 ± 58.5 62.2 (11.5–417.5) 131 (87.3) 79.2 ± 68.6 62.01 (2.5–436.5)
1× per week 103 (100.0) 65.9 ± 57.8 48.8 (2.3–335.0) 88 (85.4) 80.9 ± 96.8 47.5 (0.0–622.6)
Dialysis type
Predialysis 32 (100.0) 87.7 ± 73.5 56.0 (19.1–335.0) 26 (81.2) 122.6 ± 133.3 73.2 (14.9–622.6)
Haemodialysis 288 (100.0) 82.3 ± 57.9 66.5 (2.3–396.0) 242 (84.0) 90.5 ± 102.6 69.0 (0.0–1293.6)
Peritoneal dialysis 91 (100.0) 89.8 ± 107.3 60.4 (12.2–804.0) 77 (84.6) 88.8 ± 92.4 61.9 (4.4–436.5)
Total 411 (100.0) 84.4 ± 72.7 64.8 (2.3–804.0) 345 (83.9) 92.5 ± 103.1 66.0 (0.0–1293.6)
Table 5: Adverse events (AE) considered possibly related to 
treatment and reported in ≥ 0.5% of patients (safety-evaluable 
population; N = 478)
AE Number (%) of patients
Total 59 (12.3)
Hypertension 14 (2.9)
Thrombosis 9 (1.9)
Anaemia 5 (1.0)
Injection site pain 5 (1.0)
Laboratory test abnormal* 4 (0.8)
Erythrocyte abnormal 3 (0.6)
Headache 3 (0.6)
*Laboratory test abnormal was the coded term for haemoglobin 
elevation (n = 2) and iron deficiency (n = 2)BMC Nephrology 2009, 10:5 http://www.biomedcentral.com/1471-2369/10/5
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Our study has some limitations. The study was not
blinded and did not include a control group and therefore
results could possibly be due to factors other than treat-
ment with epoetin delta. As entry criteria resulted in a
study population that was previously responsive to epoe-
tin treatment, our data provide no information on
whether some patients may respond better to epoetin
delta. It should also be noted that this study was com-
pleted before recent evidence regarding the potential
harmful effects of fully correcting haemoglobin levels.
From our data, we can not draw any conclusion as to
whether epoetin delta was associated with any risk or ben-
efit when associated with relatively high haemoglobin lev-
els.
Further studies are underway to investigate potential ben-
efits arising from the human-cell production of epoetin
delta.
Conclusion
In this 52-week trial subcutaneously administered epoetin
delta was shown to be an effective agent for the manage-
ment of anaemia in patients with CKD. Predialysis
patients and patients requiring peritoneal dialysis or
haemodialysis were all able to maintain haemoglobin lev-
els within the specified range, without marked changes in
dosing regimen. Epoetin delta was well tolerated for treat-
ment of up to 1 year and there was no evidence that it was
capable of eliciting an immune response.
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